You are viewing an expired study

Jamaica Plain, Massachusetts 02130

  • Schizophrenia

Purpose:

This study will determine the effectiveness of clozapine versus olanzapine in treating people with schizophrenia that has not improved with treatment.


Study summary:

This is a two-year open-label, randomized trial of the comparative effectiveness of clozapine versus olanzapine in patients with treatment refractory schizophrenia. The objective is to determine whether in a naturalistic setting olanzapine is a logical treatment choice (before using the more toxic clozapine) for some treatment refractory patients.


Criteria:

Inclusion Criteria: - Age 20-60 years; - Diagnosis of treatment refractory schizophrenia or schizoaffective disorder; - BPRS score > 21 (0-6) scale; - Either two 6-8 week trials of typical neuroleptics given at a dosage of 600 mg/day of CPZ or its equivalent or one 6-8 week trial of an atypical antipsychotic at a reasonable dose (i.e. risperidone 4-6 mg/day); - The patient (or the patient's authorized legal representative) must understand the nature of the study and sign the informed consent; - Clinically appropriate for clozapine or olanzapine Exclusion Criteria: - Current substance abuse; - Suicide or homicide risk; - Pregnancy or lactation; - History of seizures or blood dyscrasias


NCT ID:

NCT00169065


Primary Contact:

Principal Investigator
Alan I Green, MD
Harvard Medical School


Backup Contact:

N/A


Location Contact:

Jamaica Plain, Massachusetts 02130
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.